What Ryght AI does

Ryght AI is a privately-held healthcare technology company that builds an enterprise-scale generative AI platform purpose-built for clinical trials. Its core technology is the AI Site Twin — a digital replica of every clinical research site that captures operational characteristics, historical trial performance, and patient populations, continuously updated by AI retriever agents pulling from public and proprietary data streams. The company reports coverage of 100,000+ research sites across 192 countries via 60,000+ AI Site Twins, and a published CRO case study shows site selection timelines compressed from 6 months to 26 days, delivering 43 qualified sites against a target of 13. The platform comprises the Ryght AI Platform (with Network Navigator for AI site selection, Feasibility Accelerator for AI-powered questionnaire distribution, and the Ryght Research Network), the free public-facing RyghtSites.com search engine, and the free Ryght Preview GenAI platform with copilots for life sciences knowledge workers. The architecture is multi-LLM and vector-database orchestrated, SOC 2 Type II, HIPAA-aligned, and ISO certified, and is available on the Microsoft Azure Marketplace.

Name

Ryght AI

Legal name

Ryght, Inc.

Website

https://ryght.ai

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Ryght AI is an enterprise generative AI platform for clinical trials, building AI Site Twins — digital replicas of 100,000+ research sites across 192 countries — and serving pharmaceutical sponsors, CROs, and academic medical centers to compress site selection and feasibility timelines.

Ownership category

akta.pro rank

Product category

Clinical Trial Technology

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Clinical trial AI
• Site selection software
• Generative AI platform
• Clinical research technology
• Digital twin technology

Headquarters

HQ city

Laguna Beach

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Subscription (Enterprise SaaS): Recurring subscription revenue from pharmaceutical sponsors and CROs accessing the Ryght platform (Network Navigator and Feasibility Accelerator). Per the Terms of Service, fees are auto-billed on a subscription billing date; pricing is reserved at the company's discretion with advance notice of changes. Sponsors and CROs pay; research sites access the base applications free of charge.
2. Microsoft Azure Marketplace Transactions: Revenue transacted through the Microsoft Azure Marketplace, where healthcare organizations can use existing Azure cloud commitments to procure the Ryght platform. Streamlined procurement, consolidated billing, and shared go-to-market via Microsoft.
3. Free Site-Side Tier / Freemium (Sites): Base applications (including Feasibility Accelerator) are free of charge to research sites globally, serving as a land-and-expand funnel: sites attract sponsor/CRO feasibility traffic, while sponsors and CROs pay for premium enterprise platform access.
4. Professional Services / Custom Build: Customized enterprise build, integration, and deployment services for life science companies, including custom copilots and integration with clients' specific data streams. (Per the company's own positioning: "Our team will also work to build and install individualized applications which seamlessly work with companies' specific data streams.")

Pricing tiers

Go-to-market motion5 records

Distribution channels6 records

Marketing channels9 records

Core offering

Ryght AI develops an enterprise-scale generative AI platform for clinical research, anchored by "AI Site Twins" — dynamic digital replicas of every clinical research site in the world that are continuously updated by AI retriever agents. The platform delivers two core products: Network Navigator (AI Site Selection) and Feasibility Accelerator (AI Site Feasibility), which compress traditional 3–6 month clinical trial site selection and feasibility workflows into days for pharmaceutical sponsors and contract research organizations (CROs).

Product overview

Ryght AI offers a platform-plus-modules architecture centered on its agentic AI platform, with the Ryght AI Platform as the unified core powered by AI Site Twins — dynamic digital replicas of every clinical research site in the world that are continuously updated by AI retriever agents. The platform integrates three main products that work together: Network Navigator (AI Site Selection) for protocol-matched, performance-ranked site lists; Feasibility Accelerator (AI Site Feasibility) for automated AI-powered feasibility questionnaire distribution and real-time tracking; and the Ryght Research Network, a global network of clinical research sites that enables real-time communication between sponsors, CROs, and sites. RyghtSites.com is the free public-facing search engine that queries the AI Site Twin network, while Ryght Preview is a free GenAI platform and Ryght GenAI Copilots are customizable AI applications for clinical research workflows. All offerings are SOC 2 Type 2-compliant and available on the Microsoft Azure Marketplace.

Differentiator

Problem solved

Functional benefit

Brands

• RyghtSites.com: Free AI-powered search engine that indexes 100,000+ global clinical research sites across 192 countries to help sponsors and CROs find clinical trial sites.
• Network Navigator
• Feasibility Accelerator
• Ryght Preview
• The Ryght Research Network
• AI Site Twins

Products and services

• Ryght AI Platform Enterprise-grade agentic AI platform for clinical research, powered by AI Site Twins (dynamic digital replicas of every clinical research site in the world). Enables sponsors and CROs to automate site selection, feasibility, patient referrals, and trial optimization with SOC 2 Type II compliance.
• Network Navigator (AI Site Selection) AI site selection solution that delivers a protocol-matched, performance-ranked site list in days. It intelligently ranks and tailors site lists to the specific needs of a protocol, compressing traditional 3–6 month site selection workflows to a fraction of the time. For sponsors and CROs.
• Feasibility Accelerator (AI Site Feasibility) Automatically sends AI-powered feasibility questionnaires to qualified sites pre-populated with data from the AI Site Twin network, with real-time response tracking and comparison. Most sites complete the questionnaire in 5–10 minutes vs. 2–4 hours traditionally. For sponsors, CROs, and research sites.
• RyghtSites.com A free AI-powered search engine for clinical trial site selection, indexing 60,000+ AI Site Twins representing 100,000+ research sites across 192 countries. Enables sponsors and CROs to search global research sites by indication, phase, and region, replacing expensive legacy data vendor contracts.
• Ryght Research Network A global network of clinical research sites connecting academic institutions, community practices, and healthcare systems with trial sponsors. Uses generative AI to automate feasibility assessments, site selection, patient referrals, and real-time communication between sites and sponsors; base applications are free of charge to research sites globally.
• Ryght Preview A free, secure GenAI platform with frictionless sign-up for life sciences knowledge workers. Pre-equipped with a growing library of tailored 'copilots' to accelerate information retrieval, synthesis, document creation, and analysis of complex/unstructured data. Built on the same underlying platform as the enterprise Ryght offering.
• Ryght GenAI Copilots A growing library of customizable GenAI-powered copilots for life science companies, including clinical trial document generation, gene variant research assistants, and data pipelining of massive unstructured healthcare datasets. Designed to reduce weeks of work to days or hours.

Quantifiable outcome

• Site selection timeline compressed from 6 months to 26 days in a CRO case study
• +4 more outcomes

Named customers14 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability11 records

Feature6 records

Partnerships

18 partnerships are on record, tiered flagship / tier 1, high and medium.

• American Society of Clinical Oncology (ASCO)flagship / tier 1Strategic or Co-development Partner · 28 May 2026Strategic collaboration (May 28, 2026) to deploy Ryght's AI Site Twin platform for automating site selection and activation for ASCO's CDK4/6 Inhibitor Dosing Knowledge Study focused on metastatic breast cancer. ASCO serves 50,000+ oncology professionals worldwide.
• BiorasihighChannel Partner/ Reseller/ Distributor · 15 August 2025Partnership (August 15, 2025) with Biorasi, a global CRO, to deliver AI-powered feasibility solutions to biotech and biopharma sponsors. Biorasi's clients gain real-time, site-specific data for more intelligent site selection.
• West Virginia UniversitymediumStrategic or Co-development Partner · 6 August 2025Joined Ryght's global site research network (August 6, 2025).
• Winship Cancer Institute (Emory University)highStrategic or Co-development Partner · 11 July 2025Partnership (July 11, 2025) deploying Ryght's AI Site Twin / digital twin platform to better match patients to clinical trials at one of Georgia's largest cancer research centers.
• Medical College of WisconsinmediumStrategic or Co-development Partner · 3 April 2025Joined Ryght's global research network (April 3, 2025) to advance AI-driven clinical trials and improve patient access.
• Cancer Research South Australia (CRSA)highStrategic or Co-development Partner · 28 January 2025Partnership (January 28, 2025) to advance cancer clinical trials in South Australia. CRSA joined the Ryght Research Network, integrating Ryght's AI-driven technology with CRSA's RealTime Clinical Trial Management systems and Xestro Electronic Medical Records.
• QPS Holdings, LLCflagship / tier 1Channel Partner/ Reseller/ Distributor · 7 January 2025Strategic partnership (January 7, 2025) under which QPS selected Ryght AI as its exclusive AI partner for clinical trial optimization and automation. QPS brings its network of 750 research sites across 17 countries into the Ryght Research Network, providing real-time communications and AI-powered site selection for QPS's biopharma clients.
• QPS Holdings, LLC (Network)flagship / tier 1Strategic or Co-development Partner · 7 January 2025Through the partnership, QPS added 750 research sites across 17 countries to the Ryght Research Network, joining USC Keck, CRSA, Medical College of Wisconsin, West Virginia University, Winship Cancer Institute, and University of Adelaide.
• University of Southern California (Keck School of Medicine)flagship / tier 1Strategic or Co-development Partner · 11 December 2024Partnership (December 11, 2024) to launch the Ryght Research Network, a global network of clinical research sites. Keck School of Medicine of USC joined the network, leveraging Ryght's GenAI capabilities to streamline site selection, feasibility, patient referrals, and study management.
• CancerXmediumStrategic or Co-development Partner · 17 July 2024Member of the CancerX public-private partnership (July 17, 2024) co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe) under the White House Cancer Moonshot.
• University of AdelaidehighStrategic or Co-development Partner · 4 June 2024Strategic partnership (June 4, 2024) using the Ryght AI platform to accelerate AI use cases across Australian research initiatives; collaboration with the Australian Institute for Machine Learning (AIML) leveraging Adelaide BioMed City health datasets.
• nmiblemediumTechnology or Integration · 30 April 2024Partnership (April 30, 2024) to integrate Ryght's GenAI capabilities into nmible's clinical trial participant reimbursement platform, automating data processing and enhancing security for clinical trial payment workflows.
• NVIDIA Inception ProgramhighTechnology or Integration · 12 March 2024Ryght joined the NVIDIA Inception program (March 12, 2024), gaining access to NVIDIA's resources, technical guidance, marketing support, and networking opportunities to advance its GenAI platform for life sciences.
• Lucem HealthhighStrategic or Co-development Partner · 27 February 2024Partnership (February 27, 2024) to deploy Ryght's GenAI capabilities into Lucem Health's AI SolutionOps platform, enabling new insights from longitudinal patient records for early disease detection and treatment acceleration.
• Avance ClinicalhighChannel Partner/ Reseller/ Distributor · 20 February 2024Strategic partnership (February 20, 2024) granting Avance Clinical — the largest specialist Australian and US CRO — access to Ryght's GenAI platform to optimize workflows for biotech clients across Australia, New Zealand, and North America.
• BEKHealthhighStrategic or Co-development Partner · 5 January 2024Co-development partnership (January 5, 2024) to integrate Ryght's generative AI capabilities into BEKHealth's AI-powered patient-matching software platform, accelerating site selection and patient recruitment for clinical trials.
• BEKHealth (co-marketing/clinical network)mediumGTM or Marketing Partner · 5 January 2024Beyond co-development, BEKHealth and Ryght jointly promoted their GenAI-driven patient-matching integration to life sciences customers.
• Microsoftflagship / tier 1Strategic or Co-development Partner · 24 July 2023Long-standing strategic partnership providing Ryght with access to Microsoft Azure cloud and a co-development relationship in healthcare and life sciences. Ryght's platform is available on the Microsoft Azure Marketplace (since September 23, 2025) for streamlined procurement. Ryght is a featured solution partner in the Microsoft booth at HLTH 2025. The two co-host webinars (e.g., March 2026) and have a dedicated "Microsoft + Ryght Partnership" page on the website.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Broad incumbents

• Medidata Solutions: Medidata (Dassault Systèmes) is the dominant CTMS / RTSM / eCOA platform used by most large pharma sponsors and CROs. It is a broad incumbent with overlapping capabilities in clinical trial operations and is now layering AI on top, directly competing with Ryght's AI Site Twin vision. Ryght advisor Tarek Sherif is Medidata's co-founder.
• Veeva Systems: Veeva is the leading life-sciences cloud platform (CTMS, eTMF, Vault CDB, SiteVault). It serves the same biopharma sponsor/CRO buyer as Ryght and competes indirectly via its Vault Clinical Suite and Veeva AI initiatives. A plausible enterprise consolidation target alongside Medidata.
• Oracle Health (Clinical One): Oracle's Clinical One platform is an end-to-end clinical trial platform (CTMS, RTSM, EDC) targeting the same large-pharma buyer as Ryght, with Oracle increasingly embedding AI features across its life-sciences stack. A broad incumbent competing for the same enterprise budget.
• IQVIA: IQVIA is a global CRO and clinical-trial technology vendor with proprietary site, investigator and patient data assets (e.g., IQVIA E360, IQVIA Health Data Cloud). It competes with Ryght both as a CRO channel and as an incumbent AI site-selection/data vendor.
• Tempus AI: Tempus AI is an AI-driven precision-medicine and clinical-trial enablement company with large molecular and clinical data assets used for site identification, patient matching and trial design. Broader scope than Ryght but overlapping buyer and use cases in oncology trials.

Direct peers

• Inato: Inato is a direct peer: a marketplace platform that matches clinical trials with community-based research sites, focused on improving trial access and enrollment. Targets the same sponsors/CROs and addresses the same site-selection and feasibility problem Ryght's Network Navigator solves.
• Antidote: Antidote operates a clinical-trial matching platform used by sponsors and patient communities to recruit into trials. It is a direct comparable in trial feasibility/recruitment, although its lens is patient-to-trial rather than protocol-to-site, and it competes for the same sponsor/CRO budget.
• Trial Library: Trial Library is a clinical-trial site-intelligence and feasibility platform for sponsors and CROs, focused on protocol feasibility, site identification and enrollment planning. Closely comparable to Ryght's Network Navigator and Feasibility Accelerator.

Emerging players

• BEKHealth: BEKHealth is an AI-powered patient-matching and clinical-trial feasibility platform for sponsors and research sites; it is already a Ryght co-development partner, so it is both a comparable in trial-feasibility AI and an ecosystem participant.
• Mendel: Mendel applies LLM-based AI to clinical and biomedical data to structure unstructured medical records and accelerate trial cohort identification and feasibility. Direct comparable in generative-AI for clinical-trial operations and life-sciences data.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat8 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/91444446
• Xx.com/ryghtai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ryght AI